Director of the Abramson Cancer Center of the University of Pennsylvania. Rafael Pharmaceuticals on LinkedIn, Twitter & YouTube. He is designated as a Georgia Research Alliance Eminent Scholar in Cancer in the Medical College of Georgia. To develop highly selective, well tolerated, and highly effective anti-cancer agents, by selectively targeting altered metabolism in cancer cells. Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Nov 10, 2020 Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer Learn More November 29, 2018 The "Clear Cell Sarcoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. RAFAEL PHARMACEUTICALS. A breakthrough approach to treating some of the most intractable forms of cancer, Rafael's proprietary AMD platform has produced a robust pipeline of breakthrough cancer therapies. CONTACT US . News Coverage Jan 19, 2021 Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference. RAFA | Complete Rafarma Pharmaceuticals Inc. stock news by MarketWatch. Clear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com February 09, … Investor Overview Stockholder Services Tax Documents Corporate Governance Annual Reports and Proxies Quarterly Earnings SEC Filings Investor Presentations Email Alerts Contact Investor Relations. Rafael’s first-in-class clinical lead compound, CPI-613 ® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. 4 min read. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who are working with Rafael to revolutionize anticancer treatment. CPI-613® is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. At Rafael Pharmaceuticals, Inc. we are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers. © 2021 Rafael Pharmaceuticals, Inc. All Rights Reserved, https://rafaelpharma.com/wp-content/uploads/FINAL_Rafael-MOA-Video-3D.mp4, Clinical Trial 18-443: Patients with Burkitt’s Lymphoma/Leukemia or High-Grade B-cell Lymphoma, Clinical Trial AML003: Older Patients with Acute Myeloid Leukemia (AML) – Relapsed or Refractory, Clinical Trial PANC003: Patients with Metastatic Adenocarcinoma of the Pancreas, Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference, Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference, Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue, Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer, FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma. Rafael Pharmaceuticals is a leader in metabolic oncology; learn more about the company & the cancer drugs we provide, along with a letter from our chairman. Yerba Santa helps provide enhanced moisturization and lubricity, in a manner similar to Aloe Vera. Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma, Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Congratulates Scientific Advisory Board Member Gregg L. Semenza For Receiving 2019 Nobel Prize in Medicine, Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer, Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer, Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat), Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries, Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey, Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference, Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala, Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations, CPI-613® (devimistat) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”, Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium, EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Metastatic Pancreatic Cancer, EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613® for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia, Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613® in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer, Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference, Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613®, Rafael Pharmaceuticals to Present at BIO Investor Forum 2018, Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613® for the Treatment of Peripheral T-Cell Lymphoma (PTCL), Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613® in Patients with Relapsed or Refractory T-Cell Lymphoma, Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613® in Pancreatic Cancer and Other Gastrointestinal Malignancies, Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613® for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia, Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613® in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association, Rafael Pharmaceuticals to Present at 2018 Bio International Conference, Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals’ Lead CPI-613® Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia, Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613® in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition, Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613® in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer, Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting, Rafael Pharmaceuticals to Present at 2017 BIO International Convention. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. T hrough its wholly-owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism. Access recent Rafael Pharmaceuticals news, insights on cancer metabolism, and updates on the company's innovative therapies and drugs including CPI-613®. View real-time stock prices and stock quotes for a full financial overview. In their urgent mission to save lives, PanCAN attacks pancreatic cancer on all fronts: research, clinical initiatives, patient services, and advocacy. He also currently serves as a Director of Irresistible Materials Ltd., a next generation nano materials company. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. About Rafael Pharmaceuticals, Inc. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Clear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com February 09, … Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Our primary objective is to produce highly selective and effective anti-cancer … Division Chief, Hematology and Oncology, Levine Cancer Institute, CHS-Northeast; Director of Investigational Therapeutics in Hematologic Malignancies, Levine Cancer Institute/Carolinas HealthCare System; Associate Professor of Medicine, University of North Carolina, Chapel Hill, Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center. Please check the website periodically for available positions. CRANBURY, N.J., Jan. 19, 2021 -- Rafael Pharmaceuticals, Inc. ('Rafael' or the 'Company'), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company, will present at the B. Riley Securities Virtual Oncol Dr. Sol J. Barer is a co-founder of Celgene Corporation and currently Chairman of the Board of Teva Pharmaceuticals, Chairman of Centrexion Therapeutics and Neximmune, Lead Director of Contrafect Corp, and Board member of 3DBiotherapeutics, Cerecor, founding Chair of the Hackensack Meridian Center for Discovery and Innovation and advisor to the Israel Biotech Fund. Rafael Holdings Navigation. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. October 22, 2018 at 11:57 PM. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613® as an orphan drug for the treatment of pancreatic cancer, AML, Myelodysplastic syndromes (MDS), peripheral T-cell lymphoma and Burkitt’s lymphoma. Rafael’s lead AMD compound, CPI-613 ® (devimistat), is being evaluated in 19 ongoing or completed Phase I, I/II, II and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma at OncLive TV. Please help us show Rafael Pharmaceuticals how many people they could impact by liking and sharing this post. About Rafael Pharmaceuticals, Inc. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D. Director of The Georgia Cancer Center at Augusta University. Through its … Rafarma Pharmaceuticals Inc. Rafarma Pharmaceuticals, Inc. engages in the manufacture and marketing of pharmaceutical goods. Executive … About Rafael Pharmaceuticals, Inc. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Cornerstone Pharmaceuticals, Inc. Rafael Pharmaceuticals offers an intellectually stimulating and collegial work environment, competitive compensation and benefits, and are an Equal Opportunity Employer. Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) Dec 01, 2020 Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.. Soft tissue sarcoma is a type of cancer that starts in the soft tissues of the body, such as fat, muscle, nerves, fibrous tissues, blood vessels or deep skin tissues. Find the latest Rafael Holdings, Inc. (RFL) stock quote, history, news and other vital information to help you with your stock trading and investing. Rafael Pharmaceuticals To Save a Life Is To Save A Universe ™ It has been known for nearly a century that cancer cells have a unique metabolism compared to normal cells. Rafael Pharmaceuticals is a provider of metabolic oncology therapeutics intended to treat cancer patients. RAFAEL HOLDINGS, INC. : News, information and stories for RAFAEL HOLDINGS, INC. | Nyse: RFL | Nyse John Hill. Developing innovative cancer therapies that will transform the way we treat patients. Scientists at Rafael Pharmaceuticals believe their new drug, CPI-613, is a breakthrough for people suffering from some of the most devastating types of cancer, such as pancreatic, lymphoma and lung. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards. Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer. Sunesis Pharmaceuticals, Owens & Minor leads healthcare gainers; Rafael, Constellation Pharmaceuticals among major losers Feb. 24, 2021 10:59 AM ET Sunesis Pharmaceuticals… Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors. Rafael Holdings Investor Presentation - LD Micro - September 2020: Real Estate Holdings; Rafael Pharmaceuticals; Lipomedix Pharmaceuticals; Leadership The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals… It produces all types medical drugs in … Announces Corporate Name Change to Rafael Pharmaceuticals, Inc. Rafael Holdings is focused on development of novel cancer therapies. This report provides comprehensive insights about 6+ … News Break; rafael pharmaceuticals. Rafael Pharmaceuticals has 2,037 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland). Not-little Orphan ante, more HCU Warbucks ahead in $517M Retrophin deal. CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of … Rafael Pharmaceuticals has sponsored PanCAN PurpleStride Walks to end Pancreatic Cancer across the country. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. My mom is a perfect candidate to help them fulfill their stated mission, so please allow her access! Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University, Detroit, MI. Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017, Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613® in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016, Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer, Cornerstone Pharmaceuticals to Present New Data on CPI-613® at the American Society of Hematology 2016 Annual Meeting, IDT Corporation Announces Investment in Cornerstone Pharmaceuticals, Cornerstone Pharmaceuticals Announces Acceptance of Abstract on CPI-613® Pancreatic Cancer Trial by European Society for Medical Oncology (ESMO) Congress 2016, Cornerstone Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, Cornerstone Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613® in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium, Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting, Cornerstone Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Metastatic Colorectal Cancer, Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613® for the Treatment of B-Cell Non-Hodgkin Lymphoma, Cornerstone Pharmaceuticals’ CPI-613® Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch, Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613® in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma, Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer, Cornerstone Pharmaceuticals’ CPI-613® Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research, Cornerstone Pharmaceuticals Clinical Data on CPI-613® to be Presented at ASCO 2014, Cornerstone Pharmaceuticals’ CPI-613® Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting, Cornerstone Pharmaceuticals Lead Compound CPI-613® Demonstrates Ability to Disrupt Growth of Cancer Cells, Cornerstone Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613® at 2014 Special Conference of American Association for Cancer Research, Cornerstone Pharmaceuticals Appoints Dr. Chi Van Dang to Scientific Advisory Board, Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613® at 2013 American Society of Hematology Annual Meeting, Cornerstone Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop, Cornerstone Pharmaceuticals to Present CPI-613® Phase I Results at 2013 American Society of Hematology Annual Meeting, Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® in Patients with Locally Advanced or Metastatic Pancreatic Cancer, Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® for the Treatment of Small Cell Lung Cancer, Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613® for Treatment of Myelodysplastic Syndrome, Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® for the Treatment of Myelodysplastic Syndrome, Cornerstone Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Acute Myelogenous Leukemia, Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® for the Treatment of Advanced Bile Duct Cancers, Cornerstone Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting, Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® in Patients with Advanced Solid Tumors, Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer, Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism, Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference, Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual ASCO Meeting, Cornerstone Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy, Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual AACR Meeting, Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613®, showing promise in Phase I trial for acute myeloid leukemia, Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston, Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology, Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613® for patients with acute myeloid leukemia, Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds, Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613® in Acute Myeloid Leukemia, Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study, Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program, Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference, Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences, Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations, Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613®, Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development, Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613® for Hematologic Malignancies, Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute, Dr. Robert Shepard Appointed Chief Medical Officer for Cornerstone Pharmaceuticals, Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613®, Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects, Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer, Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D., to its Scientific Advisory Board, Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613® for Treatment of Pancreatic Cancer, Cornerstone Pharmaceuticals Announces $6M Financing to Further Advance Clinical Trials in Cancer Patients, Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613® for the Treatment of Cancer, Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613® in Cancer Patients by US FDA.

Galactic Toys Review, Clinical Research And Development, George Brown Cooking Classes For Fun, Cheryl White Billy Paul Jones, The Little Things Scary, Bookxcess Discount Code 2021, One More Hour Tab, Vivo Emergency Call Setting, California Insurance Commissioner Complaints, Ntuc La Gourmet 2020,